Analyst Soumit Roy of JonesTrading maintained a Buy rating on Precision BioSciences, retaining the price target of $30.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Soumit Roy has given his Buy rating due to a combination of factors that highlight Precision BioSciences’ promising advancements in genetic medicine. The company’s innovative in vivo gene editing programs, particularly in chronic hepatitis B virus (HBV) and Duchenne muscular dystrophy (DMD), are seen as highly differentiated and hold significant potential. The anticipated data updates in 2026, including maturing HBV data and initial DMD data, are expected to be key value drivers for the company.
Recent data from the Phase 1 ELIMINATE-B trial demonstrated substantial reductions in hepatitis B surface antigen (HBsAg) levels among patients, indicating a strong potential for a functional cure. The promising results from the 0.8 mg/kg dose cohort, which showed significant HBsAg reduction after just one dose, further support the company’s innovative approach. Additionally, the observed viral DNA editing in patients confirms the activity of PBGENE-HBV, while the manageable safety profile enhances the attractiveness of Precision BioSciences’ therapeutic offerings.
Based on the recent corporate insider activity of 24 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of DTIL in relation to earlier this year.